Compare VanEck Australian Floating Rate ETF (FLOT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs TransMedics Group Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.94, while TransMedics Group Inc trades at $87.58 (market cap $3.10B). The key difference: VanEck Australian Floating Rate ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| FLOT | TMDX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $51.09 | $150.42 |
52-Week Low | $50.72 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.93 with minimal daily movement (+0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains consistent dividend payments with recent distributions of $0.17-$0.18. Market focus remains on Federal Reserve policy decisions and their impact on floating rate bonds amid persistent inflation concerns.
FLOT offers exposure to high-quality floating rate bonds with a 4.0% SEC yield, positioned as a conservative income vehicle. The ETF benefits from potential Fed rate hikes but faces headwinds from inflation volatility and Treasury yield fluctuations. Current technical weakness suggests cautious near-term positioning despite the defensive characteristics of floating rate securities.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
